Navigation Links
Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial

fter the welfare of the patients and diligently collected the data for analysis in this trial.

    ENQUIRIES: Dr. Tracie Ramsdale

    Chief Executive Officer

    Alchemia Limited

    Tel: +61-7-3340-0200


    RELEASED BY:

    Ms Anna Whybird

    Phillips Group

    Tel: +61-7-3230-5000

About HyACT

HyACT(TM) is a proprietary delivery technology which utilises Hyaluronic acid (HA), to deliver and enhance the retention of anti-cancer drugs within tumours. The drug becomes entrapped in a matrix of HA which binds to HA receptors located on the tumour resulting in more of the drug being delivered to the tumour cells. In preclinical studies, the HyACT(TM) technology has demonstrated improved delivery of the drug to the tumour resulting in significantly reduced toxicity and increased efficacy and survival.

About Irinotecan

Irinotecan is widely used in the treatment of metastatic colorectal cancer, and is being evaluated in many other tumour types. Like most cytotoxics the use of irinotecan is restricted by its side effects, the most significant of which are diarrhoea and neutropenia, and limited activity in some patients. Sales of Pfizer's irinotecan (Camptosar(R) ) were US$903 million in 2006, and patent exclusivity for the drug expires in 2008 in the US and 2009 in the EU.

About HyCAMP(TM)

HyCAMP(TM) is a proprietary formulation of the anti-cancer drug irinotecan. Preclinical studies with HyCAMP(TM) demonstrated improved delivery of the drug to the tumour, resulting in increased efficacy and reduced toxicity. The phase II clinical trial was initiated to evaluate HyCAMP(TM) in patients with metastatic colorectal cancer.

CLINICAL APPENDIX

The following additional information is provided in accordance with the Code of Best Practice for ASX Reporting by Life Science Companies

    Trial Title        Randomised Phase II Trial of irinotecan with Hyaluronic

                       Acid (HyCAMP(T
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:10/20/2014)... N.Y. , Oct. 20, 2014 Pharmaceutic ... outsourcing facility in Albany, NY ... trials. The company meets and/or exceeds the FDA standards ... and 21 CFR Part 211. The ... the highest levels of quality assurance and quality control. ...
(Date:10/20/2014)... -- Norgine B.V. today announced that the ... preparation, NER1006, presented at the 79 th Annual ... Philadelphia, PA , has met its ... endpoint of cleansing success. The study demonstrated high quality ... in screening colonoscopy patients. [1] (Logo: ...
(Date:10/19/2014)... , October 20, 2014 Shire plc (LSE: ... , Interim Chief Financial Officer (CFO), has notified the Board of ... to pursue a new career opportunity as CFO of Severn Trent ... and the company will commence a search for a new CFO ... "James has helped build and lead a high-quality finance team ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... Dec. 22, 2010 SCOLR Pharma, Inc., a Delaware corporation ... it notified the NYSE Amex Exchange (the "Exchange") of its ... Exchange Commission (the "Commission") to effect the voluntary withdrawal of ... to file the Form 25 with the Commission on or ...
... WPI ) today announced the U.S. Food and ... – the first and only low dose oral contraceptive to ... chewable form, with four 75 mg ferrous fumarate (iron) placebo ... proven effective in lowering the risk of pregnancy. ...
Cached Medicine Technology:SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 2SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 3SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 4Watson Announces Novel Oral Contraceptive Approval 2Watson Announces Novel Oral Contraceptive Approval 3Watson Announces Novel Oral Contraceptive Approval 4
(Date:10/20/2014)... October 20, 2014 Allegheny General Hospital’s ... that enables physicians to repair a damaged mitral valve ... MitraClip system, developed by Abbott Vascular , ... progressive and life-threatening condition in which the heart’s mitral ... flow backward from the heart’s left ventricle into the ...
(Date:10/20/2014)... hc1.com today announced the launch ... that enables healthcare organizations of all sizes to ... relationship management (“CRM”) solution. , Designed from the ... the healthcare industry, the hc1 Healthcare Relationship Cloud™ ... by combining healthcare CRM, HIPAA-compliant collaboration, and real-time ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update ... FDA on Sit and Slim II . , ... or use Sit and Slim II because it contains ... as weight loss product on various websites and possibly in ... 2010 for safety reasons, can significantly increase blood pressure and/or ...
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... (NYSE:,NTY) (http://www.NBTY.com ), a leading global manufacturer and ... cast the,presentation by Harvey Kamil, President and Chief Financial ... in New York on Wednesday,September 17, 2008., The ... NBTY,s web site, (http://www.nbty.com ) on Wednesday, September 17, ...
... Calif., Sept. 11 Abaxis, Inc.,(Nasdaq: ABAX ), ... today that Clint Severson, CEO and,President, will present at ... 17, 2008 at 8:00 a.m. EDT, at the Omni ... Abaxis develops, manufactures and markets portable blood analysis,systems ...
... Kurian, MD, and her colleagues at the Stanford University ... identify women who might have dangerous genetic mutations that ... well for white women. But they seemed to be ... repeatedly surprised when Asian women who the models predicted ...
... Wolters Kluwer Health, a,division of Wolters Kluwer, ... for students, professionals, and institutions in medicine,nursing, ... announced,today the appointment of Scott Lubeck Vice ... Lubeck comes to Wolters Kluwer Health ...
... Sept. 11 Vasculitis,Foundation (VF), the leading organization ... all types of vasculitis, is taking,its advocacy and ... of its,first-ever webinar, Monday, September 22, 12:30 - ... easily accessible information about,vasculitis to the medical community ...
... newly-developed technology at the Delft University of Technology in the ... be a thing of the past. This is the message ... Institute Delft (RID) in an article in university journal ... hospitals are facing a shortage of radio isotopes which means ...
Cached Medicine News:Health News:NBTY to Web Cast Presentation at CL King Best Ideas Conference 2Health News:Risk of breast cancer mutations underestimated for Asian women, Stanford study shows 2Health News:Risk of breast cancer mutations underestimated for Asian women, Stanford study shows 3Health News:Wolters Kluwer Health Appoints Scott Lubeck Vice President, Technology of its Professional & Education Unit 2Health News:Vasculitis Foundation Integrates Education, Outreach and Technology in First-Ever Webinar on Potentially Life-Threatening Disease 2Health News:Delft University of Technology patent for manufacturing radio isotopes 2
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
... The Johns Hopkins University Dermatology, ... Laboratory is a federally-(Clinical Laboratory Improvement ... that began operation in 1982. Its ... quality diagnostic allergy and immunology testing ...
... national reference laboratory and a laboratory ... an extensive test menu of highly ... clinical and anatomic pathology. Owned by ... clients include university teaching hospitals and ...
Sharp tipped scissors angled 135 from the shaft with a horizontal cutting action. For cutting in the plane parallel to the retina and cutting membranes adherent to the retinal surface (delamination)....
Medicine Products: